Back to Atlas
APotentially durableStandard research/education caution
CMP-0146
Discontinued investigational
UBX0101
Senolytic / p53-MDM2
Local senescent-cell clearance for osteoarthritis research
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- p53/MDM2 interaction disruption triggers apoptosis in senescent cells
- Primary market use
- Osteoarthritis / senolytic research
Pharmacology
- Molecular weight (Da)
- Not consistently disclosed
- Oral bioavailability
- N/A; local/intra-articular development
- Half-life
- ~1.5 h locally/preclinical
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical
- Clinical status
- Discontinued investigational
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Failed phase II OA endpoint; useful as historical senolytic candidate